Solrikitug

Phase 2Biologic

UUniquity One (UNI)

Solrikitug is one of 42 biologic programs targeting Eosinophilic Esophagitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eosinophilic EsophagitisActive, not recruiting

Eosinophilic EsophagitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

66 competitors in Eosinophilic Esophagitis

#DrugCompanyPhaseTrials

Flovent

PParatek Pharmaceuticals Inc

Approved

5 2

Prevacid

Cinqair

2 4

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

10 5

Tezspire

AstraZeneca

Phase 3

1 6

Fasenra

AstraZeneca

Phase 3

1 7

Xolair

Roche

Phase 2

2 8

Lialda

Takeda

Phase 2

1 9

Velsipity

Pfizer

Phase 2

1 10

Asmanex

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Eosinophilic Esophagitis

NCT06598462

Clinical

Trials by Indication[1]

Tics1 trial

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Solrikitug in Healthy Japanese and Non-Japanese Participants

Completed·UUniquity One (UNI)·Phase 1·NCT06868082·32 enrolled

Eosinophilic Esophagitis1 trial

A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

Active, not recruiting·UUniquity One (UNI)·Phase 2·NCT06598462·184 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Solrikitug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Solrikitug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Solrikitug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Uniquity One (UNI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniquity One (UNI)

Solrikitug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Tics1 trial

Eosinophilic Esophagitis1 trial

References

Drug Info

Quick Facts

Related News